Aspergillosis Drug Development Pipeline Study, H2 2018

August 2018 | 90 pages | ID: ADE4A30B038EN
VPAResearch

Abstracts

Aspergillosis Drug Development Pipeline Study, H2 2018 is the latest infectious disease publication with comprehensive information of Aspergillosis pipeline products.

DISEASE OVERVIEW

Aspergillus is a general fungus type that causes different type of infections and allergies on the basis of individual immunity levels. The mould or the fungus is observed both indoors as well as outdoors. Though healthy individuals are typically unaffected people with low immunization or damaged lungs can undergo serious illnesses such as invasive aspergillosis, Allergic Bronchopulmonary Aspergillosis%li%Chronic Pulmonary Aspergillosis and aspergilloma.

Treatment options vary on the basis of infected area and type of mould, with antifungal drugs being mostly administered to the patients.

Though the disease is not life threatening, it is widespread globally and accordingly, 20+ companies are investing their resources in developing therapeutic compounds for treatment of Aspergillus. Both drugs and vaccines can be found in global Aspergillus pipeline.

Companies currently investing in global Aspergillosis pipeline include%li%Acea Biotech Inc, Amplyx Pharmaceuticals Inc, Biosergen AS, Biothera Pharmaceuticals Inc, Cidara Therapeutics Inc, F2G Ltd, iCo Therapeutics Inc., LTN-Pharm Pharmaceutical Company, Lypro Biosciences Inc, Matinas BioPharma Holdings, Merck & Co Inc, Molecular Express Inc, Novabiotics Ltd, Pulmatrix Inc, Pulmocide Ltd, Sealife Pharma GmbH, Vical Inc and Visterra Inc.

REPORT DESCRIPTION

The Aspergillosis pipeline guide presents complete overview of drugs currently being developed for Aspergillosis. The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).

Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Aspergillosis pipeline candidate.

Research and Development progress along with latest news related to each of the Aspergillosis pipeline candidates is included.

Major companies participating in therapeutic development of Aspergillosis are included in this pipeline report. Company wise pre-clinical and clinical products along with details of drug originator, co-developers/ licensors are provided.

Amid strong interest for cure of Aspergillosis from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Aspergillosis clinical and pre-clinical products.

The report assists in identifying potential upcoming companies and drugs in Aspergillosis pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.

SCOPE OF ASPERGILLOSIS PIPELINE REPORT INCLUDES

• Panorama of Aspergillosis pipeline markets including statistics on therapeutic drugs and companies involved
• Aspergillosis Pipeline candidates across various development phases including both pre-clinical, discovery and clinical stages are covered
• Aspergillosis pipeline candidates across various ‘Mechanism of Actions’ are also presented in the study
• Overview of companies participating in Aspergillosis pipeline with short introduction to their businesses and pipeline projects
• For each pipeline candidate, drug overview, details of mechanism of Action (MOA), originator, co-developer and licensee are provided.
• Research and Development progress and trial details, results wherever available, are also included in the pipeline study
• The pipeline study provides information on all ongoing and active projects and also presents the recent news associated with Aspergillosis pipeline therapeutics

REASONS TO BUY

• Get clear understanding of the entire Aspergillosis pipeline, with details on active projects
• Get in detail information of each product with updated information on each project along with key milestones
• Know the list of companies participating in global Aspergillosis pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
• Get trial information for each pipeline product under development
• Understand the pipeline structure in terms of mechanism of Action, phase and company

Contents

I. KEY FINDINGS

1. Companies Investing in Aspergillosis Pipeline include-
  Number of Companies with Aspergillosis projects in pre-clinical Development-
  Number of Companies with Aspergillosis projects in Clinical Development-
  Aspergillosis Pipeline Companies based in Americas
  Aspergillosis Pipeline Companies based in Europe
  Aspergillosis Pipeline Companies based in Asia Pacific
  Aspergillosis Pipeline Companies based in Rest of the World
2. Pipeline Candidates include-
  Aspergillosis Pipeline Agents in pre- clinical/Discovery stage of Development
  Aspergillosis Pipeline Agents in Clinical Development stage
  Aspergillosis Pipeline Therapeutic Compounds received special status
  Mechanism of Action of most pipeline Drugs-
  Small molecules among the Aspergillosis Pipeline agents

II. INSIGHTS INTO ASPERGILLOSIS PIPELINE

1. Disease Overview
  Introduction to Aspergillosis
  Symptoms and Causes of Aspergillosis
  Treatment or Prevention Options for Aspergillosis
  Other Details
2. Phase wise Pipeline Compounds
  Aspergillosis Pipeline- Pre- Clinical/Discovery stage Drugs
  Aspergillosis Pipeline- Phase 1 stage Drugs
  Aspergillosis Pipeline- Phase 2 stage Drugs
  Aspergillosis Pipeline- Phase 3 stage Drugs
  Aspergillosis Pipeline- Pre-Registration stage Drugs
3. Company wise Aspergillosis Pipeline Compounds
4. Aspergillosis Pipeline by Mechanism of Action

III. ASPERGILLOSIS PIPELINE COMPOUND DETAILS

Corifungin
APX001
APX001A
BSG005
antifungal vaccines
CD101 IV
F901318
amphotericin B
novel peptide-based prevention and treatment of invasive aspergillosis
Mycobactovir
amphotericin B
MAT2203
posaconazole
VesiVax vaccine
Novamycin
PUR1900
PC1244
PC945
SLP0901
VL-2397
VIS-FNG
Drug Details
1. Snapshot
  Name of the Therapeutic Agent
  Originator
  Developing Company
  Co-Developer/License Partner
  Orphan Drug/Fast Track/Designation
  Development Phase
2. Drug Overview
3. Mechanism of Action
4. Current Status
5. Clinical Trial Details

IV. ASPERGILLOSIS PIPELINE COMPANY BRIEFS

Acea Biotech Inc
Amplyx Pharmaceuticals Inc
Biosergen AS
Biothera Pharmaceuticals, Inc
Cidara Therapeutics Inc
F2G Ltd
iCo Therapeutics Inc.
LTNpharm LTD
Lypro Biosciences Inc
Matinas BioPharma Holdings
Merck & Co Inc
Molecular Express Inc
Novabiotics Ltd
Pulmatrix Inc
Pulmocide Ltd
Sealife PHARMA GMBH
Vical Inc
Visterra Inc

V. LATEST NEWS AND DEVELOPMENTS IN GLOBAL ASPERGILLOSIS PIPELINE MARKET

VI. APPENDIX

1. Publisher’s Expertise
2. Research Methodology
3. Contact Information
Some of the sections depicted above may be removed or modified on the basis of information availability